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Abstract
Background: Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous
metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human
metabolome. Here we present results from a multiplatform study, in which we investigate what kind of results can presently
be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of
analytical platforms in the framework of an epidemiological study.
Methodology/Principal Findings: 40 individuals with self-reported diabetes and 60 controls (male, over 54 years) were
randomly selected from the participants of the population-based KORA (Cooperative Health Research in the Region of
Augsburg) study, representing an extensively phenotyped sample of the general German population. Concentrations of
over 420 unique small molecules were determined in overnight-fasting blood using three different techniques, covering
nuclear magnetic resonance and tandem mass spectrometry. Known biomarkers of diabetes could be replicated by this
multiple metabolomic platform approach, including sugar metabolites (1,5-anhydroglucoitol), ketone bodies (3-
hydroxybutyrate), and branched chain amino acids. In some cases, diabetes-related medication can be detected
(pioglitazone, salicylic acid).
Conclusions/Significance: Our study depicts the promising potential of metabolomics in diabetes research by identification
of a series of known and also novel, deregulated metabolites that associate with diabetes. Key observations include
perturbations of metabolic pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glyceropho-
spholipids, free fatty acids), and interaction with the gut microflora (bile acids). Our study suggests that metabolic markers
hold the potential to detect diabetes-related complications already under sub-clinical conditions in the general population.
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Type 2 diabetes mellitus is a complex disease [1], which is
characterized by abnormal hepatic glucose output, insulin
resistance and impaired insulin production [2,3]. It may be
assumed that in individuals with type 2 diabetes many metabolic
pathways are likely to be affected and presumably play a role in
their overall metabolic dysfunction. Thus, the identification of new
biomarkers and pathways can improve the characterization of
pathophysiological alterations associated with the disease condi-
tion [4]. Metabolomics is the rapidly evolving field of the
comprehensive measurement of ideally all endogenous metabolites
in a biological fluid [5,6,7,8,9,10]. Changes in metabolic profiles
are a potential source of such biomarkers [11,12,13,14]. We have
previously reported an analysis of targeted quantitative metabo-
lomics, where we have shown that many known and novel
observations of metabolic changes may be discovered using such a
metabolomics approach and that targeted quantitative metabo-
lomics provides a functional readout of the metabolic state of
diabetic mice under medication [15]. The method has the power
to identify perturbations of the body’s metabolic homeostasis and
thereby offers access to markers of metabolic pathways that are
impacted by the disease and/or medication. Such markers could
help physicians to identify patients at high risk for specific
complications, thereby allowing a personalized approach to
monitoring and preventing progression to costly co-morbidities.
The principal concept of metabolomics being able to find some
metabolites differing in a control and a type 2 diabetic group is
established. It is not our goal here to show this once again. The
questions we ask are rather ‘‘How well are different approaches
suited to attain this goal?’’ and ‘‘What are optimal settings under
which such studies can be successful?’’. Others have already
investigated these questions before [16,17,18]. However, we
believe that this topic is much too complex than to be answered
fully in a single study. For instance, the work described in the
recent paper in this journal by Lanza et al. [19] covers only a small
patient group of 7 cases and 7 controls. Our study, in contrast is
based on 40 cases and 60 controls from an epidemiological cohort.
Work reviewed recently by Madsen et al. [20] overlaps to some
extent with our study, but none of them address aspects related to
sub-clinical signals in a general population. Our focus is on
participants from epidemiological studies rather than on patients
under clinical conditions. Herein, we identify a series of diff-
erentially ‘‘expressed’’ metabolites that associate with diabetes
under sub-clinical conditions in the general population. This
question has not been addressed to this extent by any published
paper. In particular, we see our work as a pilot that bears the
potential of being scaled up to much larger sample sizes, since
population studies such as KORA eventually provide access to
much larger sample sizes, taken under rigorous standardized blood
sample collection conditions in dedicated study centers (e.g.
overnight fasting, standard protocol for serum and plasma
preparation, storage in liquid nitrogen until measurement). These
kinds of samples generally have not been available from clinical
studies until recently. It is in this light that we provide here a proof
of concept that metabolomics can uncover key metabolites
differing in a control and a type 2 diabetic group.
Obtaining the most comprehensive coverage of the metabolome
experimentally is key to identifying novel markers of diabetes using
the metabolomics approach [4,21,22]. Over the past two years we
have conducted experiments with three different fee-for-service
providers of quantitative metabolomics: Biocrates Life Sciences AG
(Austria), Chenomx Inc. (Canada), and Metabolon Inc. (USA) by
submitting to each of them blood samples from the same 100
participants of the population-based study KORA (Cooperative
Health Research in the Region of Augsburg) for metabolic
characterization. The methods and the metabolic profiling
platforms of the three companies are mostly complementary, but
also provide some overlap which allows for a certain level of cross-
validation. Biocrates and Metabolon apply tandem mass spec-
trometry (MS), whereas Chenomx specializes in nuclear magnetic
resonance (NMR) spectroscopy. Furthermore, Metabolon takes a
non-targeted approach, combining gas (GC) and liquid phase (LC)
chromatography; whereas, Biocrates applies targeted metabolo-
mics, based on pre-selected MRM pairs and isotope labeled
internal standards, with many of their methods being based on
rapid direct flow injection (FIA), however with capacity to carry
out multiple GC-MS and LC-MS protocols. NMR has the
advantage of leaving the sample intact, but requires much larger
(10-100x) sample volumes. FIA-MS is especially adapted to high-
throughput assays when large populations or time-series with
many data points are investigated. One example is newborn
screening for inborn errors of metabolism [23] where the power of
metabolomics has been shown for the early detection of many
monogenic disorders [24]. A combination of LC-MS and GC-MS
assures a maximum coverage of a wide metabolite spectrum, but is
more likely adapted to applications for metabolite biomarker
discovery studies [25]. The metabolic approaches used here are
thus technologically distinct but overlapping in targets identified.
Here we present the results from these studies, which implement
a case/control design in males aged over 55 years with type 2
diabetes. Because no single analytic technique covers the entire
spectrum of the human metabolome, we ask what kind of results
can presently be obtained in the field of diabetes research when
combining metabolomics data collected on a complementary set of
platforms in the context of the general human population. By
utilizing this comprehensive biochemical profiling approach, we
seek to identify metabolites with different concentrations in
patients with diabetes and in healthy controls, and thereby
allowing new insights into the pathophysiological progression of
this important metabolic disease under subclinical conditions.
Materials and Methods
Ethics statement
Written informed consent has been given by all participants.
This study has been approved by the ethics committee of the
Bavarian Medical Association (Bayerische Landesa ¨rztekammer).
Study population
The participants of this study were selected from the KORA F3
cohort study [26], which is an extensively phenotyped and
genome-wide genotyped sample from the general population,
conducted in 2004/2005. The total KORA F3 study (n=3006)
comprises male and female individuals aged between 35 and 84
years, who are residents of the city and region of Augsburg,
Southern Germany. Standardized examinations and tests that
were applied to the study participants have been described in
detail elsewhere [27], including clinical biochemistry and extensive
coverage of different life-style parameters by questionnaires. To
reduce the degree of natural variation in the data-set, we limited
this study to the ‘‘male above 54 years’’ sub-population. 40
individuals with self-reported ‘‘type 2 diabetes’’, validated by a
physician diagnosis, and 60 randomly age matched healthy
individuals who were fasting at the time of blood collection were
selected from that sub-population as case/control groups for this
study. A comparison of the basic characteristics of the diabetes and
the control groups are presented in Table 1.
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For collection of blood samples for metabolic analysis, F3 study
participants were invited again in 2006. To avoid variation due to
circadian rhythm, blood was drawn in the morning between 8 and
10 am after a period of overnight fasting. After venous puncture,
material was immediately horizontally shaken (10 min), and for
the serum tubes, followed by a 40 min resting period at room
temperature to obtain complete coagulation. After centrifugation
(2000 g; 4uC) serum was aliquoted and kept for 2–4 hours on ice,
after which it was flash-frozen to 280uC until analysis. EDTA-
blood was horizontally shaken (15 min) and thereafter centrifuged
at 4uC for 10 min at 2000 g. Plasma was transferred to new tubes
without aspirating blood cells. Aliquots were kept for 2–4 hours at
4uC and then stored at 280uC.
Metabolomics measurements
Metabolite detection and quantification was conducted by the
metabolomics providers Biocrates Life Sciences AG (Innsbruck,
Austria), Chenomx Inc. (Edmonton, Canada), and Metabolon Inc.
(Durham, USA). The companies had no access to phenotype
information that would have permitted any data pre-filtering other
than objective quality control for measurement errors based on
internal controls and duplicates. All metabolomics data was used
as received, no data correction was applied, and no data points
were removed. The quality control process applied by these
companies is described in Text S1.
Biocrates platform. A targeted profiling scheme was used to
quantitatively screen for known small molecule metabolites using
multiple reaction monitoring, neutral loss and precursor ion scans.
For the present study, a subset of the available analytical methods was
selected:201metabolitescovering the compound classesamino acids,
biogenic amines and polyamines, reducing mono- and oliogo-
saccharides, glycerophospho- and sphingolipids, eicosanoids and
other oxidized polyunsaturated fatty acids were detected and
quantified. Absolute quantitation of the metabolites in the bio-
logical sample was achieved by reference to appropriate internal
standards which are structurally identical but labeled with stable
isotopes such as deuterium,
13C, or
15N. The method has been
proven to be in conformance with FDA-Guideline "Guidance for
Industry - Bioanalytical Method Validation (May 2001’’), which
implies proof of reproducibility within a given error range.
Concentrations of all analyzed metabolites are reported in mM
(except for eicosanoid concentrations which are reported in nM units
in the supplementary data files). This data set is a subset of another
data set that has already been analyzed in the context of a genome
wide association study [28], for the discovery of biomarkers of
smoking [29] and a metabolome wide association with coffee
consumption [30]. The full dataset comprises additional data from
healthy individuals who have not been analyzed on the two other
metabolomics platforms used here, and data for metabolites with a
high fraction of missing values (.10%) was excluded here to avoid
spurious associations due to small sample sizes.
Chenomx platform. Samples were prepared for NMR
analysis using Chenomx SOP (CMX002). This platform included
micro-filtration of samples using a 3 kDa MWCO filter and the
addition of (3-trimethylsilyl) propanesulfonic acid (DSS) as an internal
standard. Spectra were acquired on a 600 MHz Varian INOVA
spectrometer. Thirty-two transients were recorded at a temperature
of 298 K. Spectra were processed and CNX files were generated
using the Processor module in Chenomx NMR Suite 5.11.
Metabolites were identified and quantified using the Profiler and
Library Manager modules in Chenomx NMRSuite 5.11 (library
version: pH 6–8, containing 292 metabolites). The methods for
identification and quantification of the metabolites were determined
as previously described [31]. Altogether, 24 metabolites were
identified in the EDTA plasma samples, including alcohols, amides,
amines, amino acid derivatives, amino acids, aromatic compounds,
fatty acids, food/drug components, organic acids and sugars. For this
study, due to the fact that only 500 ml of prefiltered plasma were
available, samples had to be diluted by a minimum of 2 times its
original volume, thereby reducing the overall sensitivity of the
method and the number of detected metabolites.
Metabolon platform. Metabolon developed a platform that
integrates the chemical analysis, including identification and
relative quantification, data reduction, and quality assurance
components of the process. The analytical platform incorporates
two separate ultra-high performance liquid chromatography/
tandem mass spectrometry (UHPLC/MS/MS2) injections and
one GC/MS injection per sample. The UHPLC injections are
optimized for basic species and acidic species. This approach
permitted the detection of 257 small molecules, with total
instrument analysis time of 24 min (two injections at 12 min
each), while maintaining a median process variability for all
compounds of 9%. Metabolon also has the ability to measure
additional compounds that do not currently have a chemical
standard, but this was not done in this study. The resulting MS/
MS
2 data were searched against an in-house generated authentic
standard library that included retention time, molecular weight
(m/z), preferred adducts, and in-source fragments, includingtheir
associated MS/MS spectra for all molecules in the library. The
library allowed for the rapid and high-confidence identification of
the experimentally detected molecules based on a multi-parameter
match basis without need for additional analyses. This integrated
platform enabled the high-throughput collection and relative
quantitative analysis of analytical data and identified a large
number and broad spectrum of molecules with a high degree of
confidence [25]. The Metabolon platform has, among other
studies, been successfully applied in the analysis of the adult
human plasma metabolome [32] identification of sarcosine as a
biomarker for prostate cancer [33], and biomarkers of insulin
resistance in a nondiabetic population [34].
Statistical analysis
The statistical analysis system R (Version 2.6.0, http://www.
r-project.org/) was used for metabolome-wide analyses and SPSS
Table 1. Characteristics** of the diabetic and the control
group.
Diabetes Non-diabetes p-value
N4 0 6 0
Age range 55–79 55–79
Age (years) 67.7 [7.2] 65.6 [6.4] .0.05
Cholesterol (mg/dl) 197.17 [40.6] 219.17 [35.4] 0.0066
HDL (mg/dl) 50.50 [16.0] 56.71 [12.9] 0.041
LDL (mg/dl) 120.50 [37.5] 137.81 [35.4] 0.026
Triglycerides (mg/dl) 208.39 [258.3] 157.42 [106.4] .0.05
HbA1c (%)* 5.95 [0.72] 5.29 [0.37] 3.0610
28
BMI* 30.01 [3.6] 28.31 [3.4] 0.019
Waist-Hip-Ratio* 0.990 [0.049] 0.957 [0.054] 0.0021
*determined at baseline 2004/2005, about 1–2 years prior to sampling for
metabolomics.
**mean [standard deviation].
doi:10.1371/journal.pone.0013953.t001
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on a case-by-case basis. Statistical association queries with
phenotype ‘‘diabetes’’ were tested in a linear model using body
mass index (BMI) as a covariate. Partial eta-square values are
reported as a measure of effect size. To correct for multiple testing,
the positive false discovery rate was used by computing q-values
after Storey and Tibshirani [35]. Motivated by our previous
observations [15,28] that the use of ratios may lead to a strong
reduction in the overall variance, we computed and tested all
possible pairs of metabolite concentration ratios. A strong
reduction in p-value (p-gain) indicates that two metabolites may
be linked by a metabolic pathway that is impacted by the diabetes
state of the patients. Dependant variables (metabolite concentra-
tions and concentration ratios) were log-scaled prior to computing
the statistics. Note that testing ratios between two metabolites a
and b is independent of their order, as log(a/b)=2log(b/a), which
halves multiple testing burden. For concentration ratios, only
statistically significant associations that display a p-gain greater
than 241 are further analyzed. This limit is considered as a
Bonferroni-type conservative cut-off for identifying those metab-
olite concentration pairs for which the use of ratios strongly
improves the strength of association. Un-scaled variables and a
parameter-free Kendall test were also used to confirm the
statistical robustness of the associations. P-values for these tests
are reported as supplementary data.
Covariates
In order to identify a metabolic signature associated with anti-
diabetic treatment at a statistically significant level, the sample size
of our study is still quite small. However, in order to test for
potentially confounding factors, we analyzed the impact of the
following diabetes-related treatments on our results: lipid-lowering
medication (excluding plant based), blood pressure lowering
medication, antidiabetic medication (insulin or oral), statin
treatment, insulin therapy, oral antidiabetic medication, calcium
antagonists, beta blockers, diuretics, and ACE inhibitors. We also
tested the influence of other factors, including age, smoking habits,
body mass index (BMI), waist-hip-ratio, alcohol consumption,
physical activity, and myocardial infarction. Finally, we tested the
effect of antidiabetic medication (insulin or oral), insulin therapy,
and oral antidiabetic medication on the metabolite spectrum for
the diabetic group alone. The details of these additional statistical
tests are provided as supplemental data.
Results
The metabolomic dataset
In the final data set, 482 distinct values of absolute (Biocrates
and Chenomx) or relative (Metabolon) metabolite concentrations
were available for analysis (Figure 1). 50 metabolites were
quantified on more than one platform: Ten metabolites were
measured on the Biocrates and the Chenomx platform, 39 on the
Biocrates and the Metabolon platform, 19 on the Chenomx and
the Metabolon platform, including 9 metabolites that were
measured on all three platforms. Thus, a total of 423 unique
metabolites were quantified on at least one platform. Comparisons
of the 68 duplicate measurements revealed that correlation
coefficients (R) between the platforms showed a median correla-
tion coefficient of 0.61 (Figure S1). In three cases no correlation
was found, indicating that the different techniques may be
measuring different metabolites here de facto. In other cases, very
strong correlation (up to R=0.95) between at least two of the
platforms was observed, showing that in principle cross-platform
replication may be possible (Figure S2; data provided as Table S1).
Associations of metabolites with diabetes
Table 2 provides metabolites that display significant differences
between the case and the control group after controlling for
multiple testing using the positive false discovery rate [35]
(q-value ,0.05). In total, associations with 482 metabolites were
tested (423 unique), with 201 metabolites from Biocrates, 257 from
Metabolon, and 24 from Chenomx. 32 associations display a
positive false discovery rate that is smaller than 5%, and 114
associations are significant with a p-value smaller than 0.05 (data
provided in Table S2). Table 3 lists metabolite pairs that display
significant increase in the strength of association when using ratios
(p-gain.241), thereby indicating that these metabolite pairs are
possibly linked through some diabetes-related metabolic or
regulatory process. The full set of associations is provided in
Table S3.
In line with our expectations, the strongest positive associations
with diabetes are observed for the numerous sugar metabolites
that were observed on the three platforms. Concentrations of
glucose, mannose, desoxyhexose (primarily deoxyglucose), uronic
acid (primarily glucuronic acid), dihexose (primarily maltose), and
several products from the biosynthesis or the degradation of
glycosylated proteins or glycolipids (H3-HNAc2-NANA, HNAC,
HNAc-H2-dH) are all found increased by up to 90% in the
diabetes group (p=1.3610
24 to 2.5610
29). Furthermore, there is
a significant decrease of average 1,5-anhydroglucitol concentra-
tions by 37.8% (p=5.1610
26) in participants with diabetes when
compared to the control group (Figure 2).
Among the numerous glycerophospholipids that are determined
on the Biocrates platform, the phosphatidylcholines PC_aa_C34:4
(p=6.5610
24) and the lyso-phosphocholine PC_a_20:4
(p=1.4610
23) display marked negative associations with diabetes,
followed by many other PC-species with poly-unsaturated fatty acids
(PUFAs) in their lipid side chains, although with lower, but still
significant strengths of association (PC_ae_C40:1, PC_ae_C36:3,
Figure 1. Venn diagram showing the number of metabolites
c o m m o nt oa l lt h r e ep l a t f o r m s ,t ot w op l a t f o r m sa n d
metabolites detected specifically by one platform. The identity
of the individual metabolites that are measured on each platform is
provided in Table S2. Note that the metabolites metabolites that are
quantified uniquely on the Biocrates platform carry specific information
on the lipid side-chain composition of the different phospholipid classes
(sometimes also referred to as lipidomics). The Metabolon platform, in
contrast, provides a wider non-targeted, but semi-quantitative coverage
of the general metabolome. NMR presently allows quantifying only a
smaller set of metabolites, but this at a much higher degree of
reproducibility, faster, and without specific sample preparation.
doi:10.1371/journal.pone.0013953.g001
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ethanolamines with similar lipid side chain compositions
(PE_aa_C34:2, PE_aa_C36:2, PE_aa_C38:4, …) display an increase
in the diabetes group. For example, statistically significant associa-
tions (p=2.628.3610
25) are observed in particular when ratios with
beta-hydroxyisovalerate are considered. Concentrations of medium-
chain length fatty acids and arachidonate are on average lower in the
diabetes group, while other long chain fatty acids are higher,
including a number of PUFAs,such as the essential fatty acids linolate
and linolenate (Table 4). Note in particular that arachidonate is
incorporated into the lipid side chains of the above mentioned
(lyso)phosphatidylcholines PC_aa_C34:4 and PC_a_20:4.
The branched chain amino acids (BCAAs) leucine, isoleucine,
and valine as well as their gamma-glutamyl-derivates are all
increased in the diabetes group (Table 5). We observe highly
increased concentrations of the ketone body 3-hydroxybutyrate
(BHBA) in the diabetes group (+53.9% when measured on a MS
platform, +40.6% on the NMR platform). At the same time, the
acetate concentrations are lower, as indicated by the ratio between
acetate and BHBA (p=1.1610
24). Association with acetate alone
was not significant. 3-indoxyl sulfate (IS) concentrations are on
average 42.8% higher in the diabetes group (p=1.7610
24).
Additionally, creatinine concentrations are found to be increased
by over 16% in the diabetes group. The association of the cysteine
to creatinine ratio with diabetes (p=1.1610
26) increases by a
factor of 289.5 when compared to the association of the single
metabolites alone, with cysteine concentrations found decreased in
the diabetes group and creatinine values increased. Similarly, the
association of ratios between cysteine and IS (p=6.8610
27)
increases by a factor of 242.7.
Some metabolites were detected in only a limited number of
study participants. Salicyluric glucuronide was detected in 16 of 40
subjects with diabetes and in 8 of 60 controls (two-sided exact
Fisher test: p=0.0037). In three patients with diabetes, both
pioglitazone and hydroxypioglitazone were detected, confirming
the intake of diabetes-specific medication; whereas none were
observed in the control group. Erythritol, a naturally-derived sugar
substitute, was found to be associated with diabetes in ratios with
Table 2. List of selected metabolites that associate with diabetes at q-values ,0.05 using log-scaled metabolite concentrations
and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control
group; eta
2 is the proportion of the total variance that can be explained by the factor ‘‘diabetes’’ in the linear model; N is the
number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is
indicated by the first letter of the provider: B=Biocrates, C=Chenomx, M=Metabolon.
Metabolite Pathway %-change N p-value q-value eta
2
1,5-anhydroglucitol [M] Sugar 237.8% 98 5.1610
26 3.2610
24 19.6%
desoxyhexose (DH) [B] Sugar 40.2% 99 1.3610
26 9.4610
25 21.6%
glucose [C] Sugar 39.3% 100 5.0610
28 7.4610
26 26.3%
glucose [M] Sugar 28.8% 99 2.5610
29 1.1610
26 30.8%
H3-HNAc2-NANA [B] Sugar 90.0% 99 2.4610
28 5.3610
26 27.6%
HNAC [B] Sugar 18.0% 99 6.2610
25 2.8610
23 15.3%
HNAc-H2-dH [B] Sugar 64.8% 99 8.2610
28 9.1610
26 25.8%
uronic acid [B] Sugar 45.8% 99 8.0610
24 1.7610
22 11.0%
dihexose (H2) [B] Sugar 65.2% 99 2.7610
25 1.5610
23 16.7%
mannose [M] Sugar 34.9% 99 2.4610
27 2.1610
25 24.2%
caproate (6:0) [M] Fatty acid, saturated, even 216.1% 99 1.5610
23 2.7610
22 9.9%
heptanoate (7:0) [M] Fatty acid, saturated, odd 215.4% 99 5.2610
24 1.3610
22 11.7%
pelargonate (9:0) [M] Fatty acid, saturated, odd 212.6% 99 1.9610
23 2.9610
22 9.5%
glycerophosphorylcholine [M] Glycerolipid 216.5% 98 4.2610
24 1.2610
22 12.2%
PC a C20:4 (alt) [B] Glycerolipid 219.1% 100 1.4610
23 2.7610
22 9.9%
PC aa (OH, COOH) C28:4 [B] Glycerolipid 216.4% 100 1.7610
23 2.8610
22 9.6%
PC aa C34:4 [B] Glycerolipid 226.0% 100 6.5610
24 1.5610
22 11.2%
SM C14:0 [B] Sphingolipid 218.7% 100 1.2610
23 2.3610
22 10.2%
SM C22:2 [B] Sphingolipid 216.3% 100 3.3610
23 4.6610
22 8.5%
creatinine [M] Creatine 19.4% 99 3.2610
24 9.6610
23 12.5%
glutamylvaline [M] Dipeptide 26.4% 99 2.9610
24 9.6610
23 12.7%
gamma-glutamylisoleucine [M] g-glutamyl 27.8% 92 6.7610
24 1.5610
22 12.1%
3-hydroxybutyrate (BHBA) [M] Ketone bodies 53.9% 99 1.9610
23 2.9610
22 9.5%
phenylacetylglutamine [M] Phenylalanine & tyrosine 76.5% 99 6.2610
25 2.8610
23 15.3%
phenylalanine [B] Phenylalanine & tyrosine 9.0% 100 2.4610
23 3.6610
22 9.0%
3-indoxyl sulfate [M] Tryptophan 42.8% 99 1.7610
24 6.1610
23 13.7%
kynurinine [B] Tryptophan 21.8% 100 5.0610
24 1.3610
22 11.7%
homocitrulline [M] Urea cycle; arginine-, proline-, 73.4% 85 3.1610
24 9.6610
23 14.6%
doi:10.1371/journal.pone.0013953.t002
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diabetes and only in 31 of 60 controls (p=0.041). Finally,
kynurenine levels are found to be 14.6%–21.8% higher in the
diabetes group. The bile acid cholate was detected in only 28 of 40
Table 3. List of selected metabolite concentration ratios that associate with diabetes at q-values ,0.05 and that display a
significant increase in the strength of association (p-gain.241) after Bonferroni correction; based on log-scaled metabolite
concentration ratios and assuming a linear model.
Lower in diabetes Higher in diabetes Pathway Pathway N p-value q-value eta2 p-gain
1,5-anhydroglucitol [M] desoxyhexose (DH) [B] Sugar Sugar 97 4.7610
29 9.0610
26 30.5% 271.6
1,5-anhydroglucitol [M] Dihexose (H2) [B] Sugar Sugar 97 2.0610
28 1.7610
25 28.3% 254.3
PC aa C34:4 [B] 3-indoxyl sulfate [M] Glycerolipid Tryptophan 99 2.1610
27 6.4610
25 24.3% 775.1
pro-hydroxy-pro [M] phenylacetylglutamine [M] Dipeptide Phenylalanine & tyrosine 99 2.5610
27 7.1610
25 24.1% 246.4
heptanoate (7:0) [M] glutamylvaline [M] Fatty acid,
saturated, odd
Dipeptide 99 4.0610
27 9.8610
25 23.4% 736.8
SM C14:0 [B] 3-indoxyl sulfate [M] Sphingolipid Tryptophan 99 5.3610
27 1.2610
24 22.9% 310.7
cysteine [M] glutamylvaline [M] Cysteine Dipeptide 95 6.6610
27 1.4610
24 23.4% 442.9
cysteine [M] 3-indoxyl sulfate [M] Cysteine Tryptophan 95 6.8610
27 1.4610
24 23.4% 242.7
caproate (6:0) [M] glutamylvaline [M] Fatty acid, saturated,
even
Dipeptide 99 7.2610
27 1.5610
24 22.5% 410.3
cysteine [M] creatinine [M] Cysteine Creatine 95 1.1610
26 2.1610
24 22.6% 289.5
cysteine [M] Uronic Acid [B] Cysteine Sugar 94 1.4610
26 2.4610
24 22.5% 572.3
cysteine [M] gamma-glutamylisoleucine [M] Cysteine g-glutamyl 88 2.7610
26 3.8610
24 22.7% 249.0
cysteine [M] erythronate [M] Cysteine Aminosugars 93 4.3610
26 5.3610
24 20.8% 901.2
cysteine [M] erythritol [M] Cysteine Sugar, sugar substitute,
starch
95 7.5610
26 7.9610
24 19.5% 656.4
cysteine [M] N-acetylalanine [M] Cysteine Valine & (Iso)Leucine 94 1.5610
25 1.3610
23 18.6% 379.9
arachidonate (20:4n6) [M] Isoleucine [C] Fatty acid, polyene Valine & (Iso)Leucine 99 2.0610
25 1.6610
23 17.2% 274.4
uridine [M] 2-methylbutyroylcarnitine [M] Pyrimidine Carnitine 87 2.5610
25 1.8610
23 19.0% 245.2
beta-hydroxyisovalerate [M] PE aa C34:2 [B] Valine & (Iso)Leucine Glycerolipid 60 2.6610
25 1.9610
23 26.5% 949.0
beta-hydroxyisovalerate [M] PE aa C36:2 [B] Valine & (Iso)Leucine Glycerolipid 60 4.5610
25 2.8610
23 25.2% 546.0
beta-hydroxyisovalerate [M] PE aa C38:4 [B] Valine & (Iso)Leucine Glycerolipid 60 8.3610
25 4.3610
23 23.6% 294.7
uridine [M] 3-methyl-2-oxovalerate [M] Pyrimidine Valine & (Iso)Leucine 99 9.4610
25 4.8610
23 14.6% 403.4
doi:10.1371/journal.pone.0013953.t003
Figure 2. 1,5-AG and glucose (measured on Metabolon
platform). Lower 1,5-AG concentrations at higher glucose levels in
participants with diabetes when compared to the control group display the
current role of 1,5-AG as a marker for glycemic control in patients with diabetes.
doi:10.1371/journal.pone.0013953.g002
Table 4. Medium chain-length fatty acids and arachidonate
are on average lower in the diabetes group, while long chain
fatty acids are higher; shown are all fatty acids that associate
with diabetes in at least one ratio pair combination with a
q-value ,5% and a p-gain .1.
Lower in diabetes Higher in diabetes
caproate (6:0) myristate (14:0)
heptanoate (7:0) palmitate (16:0)
pelargonate (9:0) 2-hydroxypalmitate
10-undecenoate (11:1n1) margarate (17:0)
arachidonate (20:4n6) 10-heptadecenoate (17:1n7)
stearate (18:0)
2-hydroxystearate
oleate (18:1n9)
linoleate (18:2n6)
linoleamide (18:2n6)
linolenate (18:3n3 or 6)
eicosenoate (20:1n9 or 11)
dihomo-alpha-linolenate (20:3n3)
adrenate (22:4n6)
doi:10.1371/journal.pone.0013953.t004
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p=0.036). Deoxycholate was found in 27 of 40 persons with
diabetes and only in 27 of 60 controls (p=0.040). Gamma-
muricholate (hyocholic acid) was detected in only 4 of 40 patients
with diabetes and in 16 of 60 controls (p=0.045).
Small peptides can be detected by the present technology when
present in sufficient concentrations. Fibrinogen alpha chain
peptides (ADpSGEGDFXAEGGGVR and ADSGEGDFXAE-
GGGVR) were found to associate with diabetes (p-value,0.05),
albeit at levels that were not significant after correcting for
multiple testing, and thus require future replication. However,
mentioning this marginal association here is noteworthy since
fibrinogen is a blood-borne glycoprotein. Various cleavage
products of fibrinogen regulate cell adhesion and spreading,
display vasoconstrictor and chemotactic activities, and are
mitogens for several cell types. There is evidence of increases in
fibrinogen peptide in the context of atherosclerotic plaque
progression [36,37].
Discussion
Before discussing the results, we should note the caveats of the
present study. These are mainly due to the history of how this
study was conducted. Consequently, we consider this work as a
pilot for future studies under more controlled conditions. Although
the concept of metabolomics as the science of measuring ideally all
small metabolites in a body fluid has been pioneered as early as
1971 by Linus Pauling [38], performing metabolomics in a high-
throughput setting is a relatively young science. One of our
objectives was therefore to evaluate its potential for use in larger
population studies [39]. Therefore, we submitted blood samples
that had been collected previously to different commercial
metabolomics providers in order to evaluate the signals that can
be detected when the data is compared to the different KORA
phenotypes [29,30]. Unfortunately, standard examinations and
collection of blood samples for metabolomics were separated by
about one to two years (see methods), introducing some
uncertainty with respect to parameters that were measured at
baseline only (e.g. body mass index, HbA1c, waist-hip-ratio,
questionnaires) and not at the time blood was sampled for
metabolomics. Some of these parameters, for instance ‘‘current
medication’’, are analyzed as covariates and results are provided as
Table S4, but should be interpreted considering this caveat.
However, blood lipid parameters were measured in the same
samples as were the metabolites.
Some of the metabolites measured on more than one platform
show only moderate levels of agreement (see results). It is not our
objective here to identify the exact reasons behind these
differences, as this would require access to proprietary information
of commercially operating companies. However, some hypothesis
on possible explanations for the less concordant measurements is
worth noting. Due to material availability serum samples had to be
used for MS, while only sufficient plasma samples were available
for NMR measurements; also the available sample volume was
suboptimal for NMR; the two MS platforms are not using
identical fractionation pattern for the identification of their
metabolites, nor do they use identical sample preparation
methods, so that dependent on the platform, in some cases ion
suppression or interference with signals from other metabolites
may occur. Finally, for funding reasons, we had to limit this study
to 100 male individuals aged above 55 years. Keeping these
caveats in mind, we will now discuss the results obtained in this
study (summarized in Table 6).
Differences in the clinical biochemistry parameters between the
diabetes and the control group are relatively modest (Table 1).
Cases with diabetes had a higher BMI and waist-hip-ratio than
control subjects. However, they did not exhibit strongly adverse
lipid profiles. Total cholesterol and LDL were actually lower in the
diabetes group, possibly a consequence of lipid lowering
medication. The average HbA1c value, albeit measured at the
base examination, was 5.95% in the diabetes group versus 5.29%
in the control group suggesting that the study participants
controlled their disease state relatively well. An important point
to note is that the metabolic signals that can be identified in such a
population study under non-clinical conditions could be expected
to be much more pronounced in a clinical setting and with
undiagnosed diabetes patients or poorly controlled diabetics.
Carbohydrate metabolism
Glucose and many related carbohydrate metabolites were
readily confirmed as a diabetes biomarker. Modified hexoses such
as N-acetylglucosamine, deoxyglucose and glucuronic acid were
all detected at higher serum concentrations in the diabetes group,
mirroring the increased supply of glucose as a precursor for their
biosynthesis. The same effect is observed by elevated maltose
levels. Alterations of glycolipid and glycoprotein biosynthesis and
degradation could possibly lead to increased serum concentrations
of complex sugars, containing N-acetylglucosamine and sialic acid
moieties. 1,5-anhydroglucitol (1,5-AG), the 1-deoxy form of
glucose is a short-term glycemic marker [40,41]. 1,5-AG is
currently used to monitor glycemic control in patients with
diabetes and is a good positive control of this study [42]. Its renal
loss, which is stimulated in hyperglycemic conditions by
glycosuria, results in lowered plasma concentrations. In agreement
with these observations we found a significant decrease of average
1,5-AG concentrations in participants with diabetes when
compared to the control group (Figure 2). A detailed analysis of
such a complex set of sugar metabolites may be combined in
future studies with additional phenotypic information, such as
lifestyle and nutrition pattern, to investigate the metabolism of
these sugar metabolites more specifically in the context of their
role in diabetic arteriosclerosis and hyperglycemia.
Table 5. Difference of average branched chain amino acids
(BCAA) concentrations between the diabetes and the control
group; a positive value %-change indicates higher
concentrations in the diabetes group; where metabolites that
were measured on more than one platform, results from these
platforms are presented separately.
Metabolite %-change p-value
glutamylvaline [M] 26.4% 2.9610
24
gamma-glutamylisoleucine [M] 27.8% 6.7610
24
isoleucine [C] 13.6% 7.8610
23
(iso)leucine [B] 8.3% 0.017
(iso)leucine [C] 13.5% 0.017
leucine [C] 13.5% 0.039
gamma-glutamylleucine [M] 12.3% 0.055
valine [B] 7.0% 0.059
leucine [M] 7.2% 0.087
isoleucine [M] 7.9% 0.095
valine [C] 7.4% 0.15
valine [M] 2.5% 0.55
doi:10.1371/journal.pone.0013953.t005
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The BCAAs leucine, isoleucine, and valine as well as their
gamma-glutamyl-derivates are all increased in the diabetes group,
indicating an impaired short-term metabolic control [43], i.e.
peripheral tissues such as skeletal muscle may have lost their ability
to react to the presence of energy sources by selective uptake
mechanisms. These observations are concordant with what is
measured in diabetic mice, where increased plasma levels of
BCAAs were also found [15], as well as in experimentally diabetic
rats [44] and in insulin-dependent type 1 diabetic human patients
[45]. Gamma-glutamyl derivates are formed in the glutathione-
dependent transport of certain amino acids. This indicates that not
only the levels of these amino acids differ between the groups, but
that also an effect on the transport of these amino acids may be
observed. BCAAs contribute to glucose recycling via the glucose-
alanine cycle [46]. There is a continuous flux of BCAAs from
visceral tissues through the blood to skeletal muscle where
transamination of the BCAAs provides the amino group for
production of alanine from pyruvate with a corresponding
movement of alanine from muscle to liver to support hepatic
gluconeogenesis [47]. Under normal conditions, alanine arising
from BCAA nitrogen likely accounts for 25% of gluconeog-
enesis from amino acids [48]. Diabetic db-/db- mice present
clear evidence of increased gluconeogenesis, visible in strongly
decreased concentrations of the gluconeogenic amino acids
alanine, glycine, and serine [15]. However, such changes are not
observed here. Glycine concentrations are not significantly
different between the two groups; alanine and serine concentra-
tions are even 6–10% higher in the diabetes group. Obviously,
study participants with diabetes do not show significantly increased
gluconeogenesis (limited validity of the mouse model) or the
consumption of the glucogenic amino acids is better compensated
by increased proteolysis.
Perturbation of lipid metabolism
It is known that the characteristic features of dyslipidemia in
humans with type 2 diabetes are high plasma triglyceride
concentration, low HDL cholesterol concentrations and increased
concentration of small dense LDL-cholesterol particles, while total
cholesterol is not increased in patients with diabetes. These lipid
changes in these individuals may be due to an increased free fatty
acid flux secondary to insulin resistance [49]. However, the
perturbations observed here in lipid metabolism reflect the state of
already treated diabetes. Association studies with blood lipid
parameters [Adamski et al., unpublished data, [50]] show that
many PC species associate with HDL and total cholesterol levels
while PE species associate with triglyceride levels. In this study, we
observed lower phosphatidylcholine (PC) and higher phosphati-
dylethanolamine (PE) concentration in the diabetes group matches
the lower HDL and total cholesterol levels and higher triglyceride
levels in this group, indicating that these glycerophospholipids may
provide a more differentiated view of the shifted lipid homeostasis
in patients with diabetes as what can be obtained from the bulk
blood cholesterol and triglyceride parameters alone. Consistent
with this finding, Gall et al. [34] observed reduced levels of
multiple acylglycerophosphocholine species that were highly
correlated with insulin resistance as measured by the euglycemic
clamp.
Mild signals of ketosis can be discerned
The two common ketones produced in humans are acetoacetic
acid and b-hydroxybutyrate [51]. Acetoacetic acid was not
measured in this study. In the diabetes group we observe highly
increased concentrations of the ketone 3-hydroxybutyrate (BHBA).
At the same time, the acetate concentrations are lower, as
indicated by the ratio between acetate and BHBA. Traditionally,
in clinical practice hyperketonemia and diabetic ketoacidosis were
predominant medical conditions in persons with type 1 diabetes.
However, newer data reveal that hyperketonemia or diabetic
ketoacidosis can also co-exist with hyperglycemia in patients with
type 2 diabetes [52]. Ketogenesis, the formation of ketone bodies
from lipid breakdown and deamination of amino acids, occurs
after depletion of the hepatic glycogen pool. In the case of
diabetes, this can be related to glucose defective absorption,
related to insulin deficiency. The concentrations of ketones
observed here probably do not correspond to a state of diabetic
ketoacidosis, but indicate that the diabetes group shows signals of
mild ketosis. A similar phenotype has previously been observed in
a clinical biomarker study on metabolic syndrome patients (three
or more ATP criteria) where the carnitine ester of BHBA was
found at significantly elevated concentrations as compared to
healthy controls (Weinberger, unpublished data).
Table 6. Overview of findings.
Observation (relative to the control group) Interpretation
Increased sugar metabolites Impaired insulin sensitivity
Reduced 1,5-anhydroglucitol Short term marker of glycemia
Decreased PCs, increased PEs Compatible with lower HDL/total cholesterol and higher triglyceride levels in patients with diabetes
Decreased medium chain-length fatty acids and arachi-
donate, increased longer chain fatty acids and PUFAs
Modification of lipid homeostasis
Increased BCAAs Increase in glucose-alanine cycle = Impaired short-term metabolic control!
Increased 3-hydroxybutyrate Marker of ketosis
Increased creatinine, 3-indoxyl sulfate, detection of pheny-
lacetate, strengthened association for cysteine to creatinine
and to 3-indoxyl sulfate ratios
Marker of nephritis, kidney function impairment and nephropathy
Detection of pioglitazone and hydroxypioglitazone, sali-
cyluric glucuronide, and erythritol
Detection of diabetes-specific xenobiotics
Reduced detection of cholate and gamma-muricholate,
increased detection of deoxycholate
Higher activity of primary into secondary bile acid conversion by gut flora?
doi:10.1371/journal.pone.0013953.t006
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3-indoxyl sulfate (IS), which is higher in the diabetes group, is
metabolized by the liver from indole, which is produced from
tryptophan by the intestinal flora. IS shows nephrotoxicity and is a
stimulating factor for progression of chronic renal failure (CRF)
[53,54]. Additional evidence for the onset of diabetic nephropathy
are creatinine concentrations, which are found to be increased
.16% in the diabetes group. Creatinine is produced in muscle
and is often increased in diabetic nephropathy. Assuming that
higher creatinine and IS values are indicators for impaired renal
function, these findings are in agreement with previous work that
shows that glomerular filtration rate (GFR) is the rate-limiting
factor for renal clearance of cysteine in patients with diabetes but
without overt nephropathy, and that hyperfiltration explains lower
than normal mean plasma total cysteine concentrations in patients
with diabetes [55]. Moreover, another study [56] suggests that an
observed increase of plasma homocysteine concentration with age
could be partly due to the deterioration of renal function. Our
results suggest that the cysteine to creatinine and the cysteine to IS
ratios are indicators of deterioration of renal function in diabetes
patients and support the idea that endogenous amino acid
catabolites, such as IS, may play a significant role in the
progression of chronic renal failure. Furthermore, phenylacetate
was more often detected in the diabetes group in this study.
Phenylacetate is a carboxylic acid ester that has been found in the
biofluids of patients with nephritis [57]. Taken together, these
results suggest that signals of the onset of renal failure can be
detected in the diabetes group, although, as we have already
pointed out in the case of ketosis, the concentrations we observe
here are still in the range that would not yet be considered as
pathogenic, but rather represent ‘‘mild’’ or ‘‘early’’ phenotypes.
These findings now need to be further verified by a quantitative
analysis from retrospective studies, especially in the light of recent
findings that L-cystine stone prevention by rational design of
crystal growth inhibitors may be possible [58].
Diabetes-specific medication can be identified
In our study salicyluric glucuronide was more frequently detected
in subjects with diabetes. Salicyluric glucuronide is the product of
the hydrolysis of acetylsalicylic acid in liver, blood and some other
organs. Detection of increased levels of this drug metabolite is
plausible considering subjects with diabetes more frequently use
drugs such as acetylsalicylic acid due to their high risk for
cardiovascular complications [59]. Furthermore, both pioglitazone
and hydroxypioglitazone were detected in individuals with diabetes
only, confirming the intake of diabetes-specific medication. In
addition, the association with erythritol could indicate a more
frequent use of sweetener by patients with diabetes. Thus,
metabolomics does not only allow the detection of naturally
occurring diabetes-related compounds, but also allows for an
external assessment of medication and intake of other xenobiotic
substances when such information is not available otherwise.
Bile acids (BAs) that can be transformed by gut bacteria
are less often detected in patients with diabetes
Cholate was detected more frequently in the control group than
in the diabetes group, while the opposite was true for deoxycholate.
Along with chenodeoxycholic acid, cholicacid is one of two primary
bile acids produced exclusively in the liver where it is synthesized
from cholesterol. Deoxycholate, also known as cholanoic acid
(3a,12a-dihydroxy-5b-cholanate), is one of the secondary bile acids
and constitutes a significant part of the circulating BA pool in
humans (35%). These secondary BAs can be either passively
absorbed to enter the BA pool or being excreted in the faeces. The
fecal loss of BAs, which is compensated for by de novo BA
biosynthesis in the liver to maintain pool size, represents a major
route for cholesterol turnover. Therefore, the present findings may
indicate that patients with diabetes exhibit alterations in the
composition of the bile acid pool, and their related biosynthetic
pathways, possibly including a higher rate of conversion of primary
to secondary bile acids by the gut microflora. Stemming from the
Figure 3. A systemic view of metabolic markers that associate with diabetes in this study. The coverage of the metabolome’s diversity
allows the detection of systemic metabolic imbalances, thereby providing a disease specific picture of human physiology.
doi:10.1371/journal.pone.0013953.g003
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the gut microbiota composition can be different between controls
and individuals with diabetes [60].
Limitations of the present study
The challenges of interpreting metabolic profiling data in a human
population include the following two points. First, a human
population is expected to display a much more heterogeneous
metabolic makeup as compared to inbred animal models under
laboratory conditions, with different environmental factors, lifestyle
and genetic background being the major contributors. Second,
human patients with diabetes will react to their diagnosed diseased
state in many ways, for example by differentially changing their
nutritional habits, level of physical exercise, and by intake of a variety
of anti-diabetic and cardiovascular-protective medications. Despite
these pronounced heterogeneities within a human diabetic popula-
tion,thepresent study with alimited samplesizewasneverthelessable
to detect many differences between patients and controls in metabolic
profiles from different pathways, lending deeper insights and
increased sensitivity for detection of a diabetic metabolic state. Many
observations presented here are consistent with what is known about
diabetes– butnotnecessarilyat clinical levels.The participantsof this
study represent a random sample of the general population, not a
specific selection of diabetes patients with acute or clinical symptoms.
They are more likely to have their diabetes under control, thereby
representing relatively mild, or possibly earlier phenotypes.
Conclusion
Our study represents the first multi-platform approach to the
metabolome-wide analyses of diabetes in a general population. The
identification of biomarkers allowing prediction of disease progres-
sion and its complications from such studies would be certainly
beneficial. However, for the caveats discussed above, we feel that
thisstudyshouldbeconsideredasa pilotforfuturework.One major
findingofourworkis the identificationofa seriesofknown,and also
some novel, deregulated metabolites that associate with diabetes
under sub-clinical conditions in the general population. These
metabolites have been discovered by integrative metabolomics
applying different platforms including nuclear magnetic resonance
(NMR) and mass spectrometry (MS). Out of the multitude of
metabolites measured, a holistic view of differences reflecting global
variations in pathophysiology emerges from our study. The
coverage of the metabolome’s diversity allows the detection of
systemic metabolic imbalances, thereby providing a disease-specific
picture of human physiology (Figure 3). A pronounced increase in
the sample size in future studies will likely allow for further detection
of other metabolites of unrecognized associations with diabetic
pathways. Finally, our study shows how functional metabolomics
can contribute to obtaining a more sophisticated classification of the
disease as well as rational optimization of diagnostic and treatment
options, as recently suggested by Bain et al. [4].
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available cross-platform correlation coefficients is provided in
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Figure S2 Selected examples of metabolites that were measured
on multiple platforms; top row: alanine concentrations measured
on Biocrates (FIA-MS), Chenomx (NMR), and Metabolon (GC-
MS) platforms; middle row: proline concentrations measured on
Biocrates (FIA-MS), Chenomx (NMR) and Metabolon (LC-MS)
platforms; bottom row: 3-hydroxybutyrate measured on Chenomx
(NMR) and Metabolon (GC-MS) platforms, acetylcarnitine
measured on Biocrates (FIA-MS) and Metabolon (LC-MS)
platforms, and arachidonic acid measured on Biocrates (LC-MS)
and Metabolon (LC-MS) platforms. Units of Biocrates and
Chenomx are in mM (absolute quantification), Metabolon reports
ion counts (relative quantification). The full dataset with all
available cross-platform correlation coefficients is provided in
Table S1.
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